Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy

Figures & data

Figure 1 Recruitment of the survey participants.

Table 1 Characteristics of the survey participants

Variable	Cream users n=100	Tablet users n=100	Total n=200
Age in years, n (%)
38–44	0 (0.0)	3 (3.0)	3 (1.5)
45–50	6 (6.0)	9 (9.0)	15 (7.5)
51–55	34 (34.0)	27 (27.0)	61 (30.5)
56–60	32 (32.0)	33 (33.0)	65 (32.5)
61–65	22 (22.0)	24 (24.0)	46 (23.0)
66–70	3 (3.0)	3 (3.0)	6 (3.0)
71–76	3 (3.0)	1 (1.0)	4 (2.0)
Mean ± standard deviation age, years	57.63 ± 5.57	57.07 ± 5.90	57.35 ± 5.74
Ethnicity, n (%)*
Caucasian	89 (89.0)	94 (94.0)	183 (91.5)
African American	4 (4.0)	2 (2.0)	6 (3.0)
Hispanic	5 (5.0)	2 (2.0)	7 (3.5)
Asian	1 (1.0)	0 (0.0)	1 (0.5)
Other	1 (1.0)	1 (1.0)	2 (1.0)
Level of education, n (%)*
Less than high school diploma or GED	1 (1.0)	0 (0.0)	1 (0.5)
High school diploma or GED	19 (19.0)	13 (13.0)	32 (16.0)
Some college education	31 (31.0)	30 (30.0)	61 (30.5)
2-year college graduate	14 (14.0)	15 (15.0)	29 (14.5)
4-year college graduate	20 (20.0)	24 (24.0)	44 (22.0)
Postgraduate degree	14 (14.0)	18 (18.0)	32 (16.0)
Marital status, n (%)*
Married	76 (76.0)	75 (75.0)	151 (75.5)
Divorced	16 (16.0)	17 (17.0)	33 (16.5)
Widowed	2 (2.0)	2 (2.0)	4 (2.0)
Never married	5 (5.0)	5 (5.0)	10 (5.0)
Status of sexual activity, n (%)*,#
Sexually active	64 (64.0)	70 (70.0)	134 (67.0)
Sexually inactive	31 (31.0)	21 (21.0)	52 (26.0)

Notes:

* Data not available for every survey participant.

# Self-defined in response to the question “Do you currently consider yourself to be sexually active or inactive?”

Abbreviation: GED, General Educational Development test.

Figure 2 Symptoms of vaginal atrophy after menopause reported by the survey participants.

Note: *P<0.05 for cream users versus tablet users.

Figure 3 Mean application time for vaginal therapy.

Figure 4 Percentages of women who overdose (A) or underdose (B) when applying their cream medication.

Figure 5 Overall satisfaction with treatment applicator.

Notes: Means are statistically significant. P-value for difference in means between tablet user group and cream user group is <0.05. A 7-point Likert Scale was used to evaluate patient satisfaction.